Prognostic Value of Serum Caspase-Cleaved Cytokeratin-18 Levels Before Liver Transplantation for One-Year Survival of Patients with Hepatocellular Carcinoma

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2016 Sep 13

PMID 27618033

Citations 12

Authors

Leonardo Lorente

Sergio T Rodriguez

Pablo Sanz

Antonia Perez-Cejas

Javier Padilla

Dacil Diaz

Antonio Gonzalez

Maria M Martin

Alejandro Jimenez

Manuel A Barrera

Affiliations

Soon will be listed here.

Abstract

Cytokeratin (CK)-18 is the major intermediate filament protein in the liver and during hepatocyte apoptosis is cleaved by the action of caspases; the resulting fragments are released into the blood as caspase-cleaved cytokeratin (CCCK)-18. Higher circulating levels of CCCK-18 have been found in patients with hepatocellular carcinoma (HCC) than in healthy controls and than in cirrhotic patients. However, it is unknown whether serum CCCK-18 levels before liver transplantation (LT) in patients with HCC could be used as a prognostic biomarker of one-year survival, and this was the objective of our study with 135 patients. At one year after LT, non-survivors showed higher serum CCCK-18 levels than survivors (p = 0.001). On binary logistic regression analysis, serum CCCK-18 levels >384 U/L were associated with death at one year (odds ratio = 19.801; 95% confidence interval = 5.301-73.972; p < 0.001) after controlling for deceased donor age. The area under the receiver operating characteristic (ROC) curve of serum CCCK-18 levels to predict death at one year was 77% (95% CI = 69%-84%; p < 0.001). The new finding of our study was that serum levels of CCCK-18 before LT in patients with HCC could be used as prognostic biomarker of survival.

Citing Articles

Post-Liver Transplant Metabolic Syndrome.

Choudhury A, Singh S, Desmukh A, Sahoo B, Eslam M J Clin Exp Hepatol. 2024; 14(4):101368.

PMID: 38523736 PMC: 10960134. DOI: 10.1016/j.jceh.2024.101368.

The prognostic potential of fragmented CK18 serum levels in HCC patients reflecting disease progression and overall hepatocyte damage.

Eguchi A, Iwasa M, Tamai Y, Yamada M, Okuno K, Shigefuku R Front Oncol. 2022; 12:993705.

PMID: 36081568 PMC: 9446083. DOI: 10.3389/fonc.2022.993705.

Non-alcoholic steatohepatitis in liver transplant recipients diagnosed by serum cytokeratin 18 and transient elastography: A prospective study.

Alhinai A, Qayyum-Khan A, Zhang X, Samaha P, Metrakos P, Deschenes M World J Hepatol. 2022; 13(12):2179-2191.

PMID: 35070018 PMC: 8727200. DOI: 10.4254/wjh.v13.i12.2179.

Nonalcoholic Fatty Liver Disease: Focus on New Biomarkers and Lifestyle Interventions.

Notarnicola M, Osella A, Caruso M, Pesole P, Lippolis A, Tutino V Int J Mol Sci. 2021; 22(8).

PMID: 33918878 PMC: 8069944. DOI: 10.3390/ijms22083899.

High Serum Caspase-Cleaved Cytokeratin-18 Levels and Mortality of Traumatic Brain Injury Patients.

Lorente L, Martin M, Gonzalez-Rivero A, Perez-Cejas A, Argueso M, Ramos L Brain Sci. 2019; 9(10).

PMID: 31658711 PMC: 6826452. DOI: 10.3390/brainsci9100269.

References

Mu H, Lin K, Zhao H, Xing S, Li C, Liu F . Identification of biomarkers for hepatocellular carcinoma by semiquantitative immunocytochemistry. World J Gastroenterol. 2014; 20(19):5826-38. PMC: 4024792. DOI: 10.3748/wjg.v20.i19.5826. View

Dumitra S, Alabbad S, Barkun J, Dumitra T, Coutsinos D, Metrakos P . Hepatitis C infection and hepatocellular carcinoma in liver transplantation: a 20-year experience. HPB (Oxford). 2013; 15(9):724-31. PMC: 3948541. DOI: 10.1111/hpb.12041. View

Yagmur E, Trautwein C, Leers M, Gressner A, Tacke F . Elevated apoptosis-associated cytokeratin 18 fragments (CK18Asp386) in serum of patients with chronic liver diseases indicate hepatic and biliary inflammation. Clin Biochem. 2007; 40(9-10):651-5. DOI: 10.1016/j.clinbiochem.2006.12.010. View

Brenner T, Rosenhagen C, Brandt H, Schmitt F, Jung G, Schemmer P . Cell death biomarkers as early predictors for hepatic dysfunction in patients after orthotopic liver transplantation. Transplantation. 2012; 94(2):185-91. DOI: 10.1097/TP.0b013e318254397c. View

Verslype C, Rosmorduc O, Rougier P . Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012; 23 Suppl 7:vii41-8. DOI: 10.1093/annonc/mds225. View

Moya A, Berenguer M, Aguilera V, San Juan F, Nicolas D, Pastor M . Hepatocellular carcinoma: Can it be considered a controversial indication for liver transplantation in centers with high rates of hepatitis C?. Liver Transpl. 2002; 8(11):1020-7. DOI: 10.1053/jlts.2002.35664. View

Hagg M, Biven K, Ueno T, Rydlander L, Bjorklund P, Wiman K . A novel high-through-put assay for screening of pro-apoptotic drugs. Invest New Drugs. 2002; 20(3):253-9. DOI: 10.1023/a:1016249728664. View

Teng F, Wang G, Tao Y, Guo W, Wang Z, Ding G . Criteria-specific long-term survival prediction model for hepatocellular carcinoma patients after liver transplantation. World J Gastroenterol. 2014; 20(31):10900-7. PMC: 4138469. DOI: 10.3748/wjg.v20.i31.10900. View

Ueno T, Toi M, Biven K, Bando H, Ogawa T, Linder S . Measurement of an apoptotic product in the sera of breast cancer patients. Eur J Cancer. 2003; 39(6):769-74. DOI: 10.1016/s0959-8049(02)00865-1. View

10.

Ulukaya E, Yilmaztepe A, Akgoz S, Linder S, Karadag M . The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival. Lung Cancer. 2007; 56(3):399-404. DOI: 10.1016/j.lungcan.2007.01.015. View

11.

Kamath P, Wiesner R, Malinchoc M, Kremers W, Therneau T, Kosberg C . A model to predict survival in patients with end-stage liver disease. Hepatology. 2001; 33(2):464-70. DOI: 10.1053/jhep.2001.22172. View

12.

Wu Y, Wang J, Wang H, Yang X . [Study on expression of Ki-67, early apoptotic protein M30 in endometrial carcinoma and their correlation with prognosis]. Zhonghua Bing Li Xue Za Zhi. 2003; 32(4):314-8. View

13.

Yilmaz Y . Systematic review: caspase-cleaved fragments of cytokeratin 18 - the promises and challenges of a biomarker for chronic liver disease. Aliment Pharmacol Ther. 2009; 30(11-12):1103-9. DOI: 10.1111/j.1365-2036.2009.04148.x. View

14.

Perneger T . What's wrong with Bonferroni adjustments. BMJ. 1998; 316(7139):1236-8. PMC: 1112991. DOI: 10.1136/bmj.316.7139.1236. View

15.

Ku N, Soetikno R, Omary M . Keratin mutation in transgenic mice predisposes to Fas but not TNF-induced apoptosis and massive liver injury. Hepatology. 2003; 37(5):1006-14. DOI: 10.1053/jhep.2003.50181. View

16.

Toyoda H, Kumada T, Tada T, Sone Y, Kaneoka Y, Maeda A . Tumor Markers for Hepatocellular Carcinoma: Simple and Significant Predictors of Outcome in Patients with HCC. Liver Cancer. 2015; 4(2):126-36. PMC: 4439793. DOI: 10.1159/000367735. View

17.

Yu D, Guo Y, Tan W, Lin D . [Functional Bax polymorphism associated with lung cancer susceptibility]. Zhonghua Zhong Liu Za Zhi. 2010; 32(5):324-7. View

18.

Luedde T, Kaplowitz N, Schwabe R . Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology. 2014; 147(4):765-783.e4. PMC: 4531834. DOI: 10.1053/j.gastro.2014.07.018. View

19.

Erdman V, Nasibullin T, Tuktarova I, Mustafina O . [Association of polymorphic markers of CASP8, BCL2 and BAX genes with aging and longevity]. Adv Gerontol. 2013; 25(3):398-404. View

20.

Varona M, Soriano A, Aguirre-Jaime A, Garrido S, Oton E, Diaz D . Risk factors of hepatocellular carcinoma recurrence after liver transplantation: accuracy of the alpha-fetoprotein model in a single-center experience. Transplant Proc. 2015; 47(1):84-9. DOI: 10.1016/j.transproceed.2014.12.013. View